We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
A Kyoto-based startup has developed the world's first cell therapy enabling nerve regeneration using ES/iPS cell-derived Schwann cells. This breakthrough enables large-scale production of cells previously difficult to mass-produce, paving the way for clinical trials.
Leveraging world-leading autophagy measurement technology, we provide end-to-end solutions from material evaluation and supplement/cosmetic development to drug discovery research. A startup demonstrating results in international competitions, aiming for the societal implementation of extended healthy lifespans.
A startup originating from the University of Tokyo and the University of Tsukuba, possessing proprietary technology for selectively amplifying hematopoietic stem cells in vitro. It aims to realize next-generation regenerative medicine through cell and gene therapies for blood disorders and genetic diseases, as well as vascular regeneration technology.
Cerebro Pharma was established in 2020 as an Osaka-based bio-venture with the mission to create a society free of dementia. We focus on research and development of healthcare products and pharmaceuticals specializing in the prevention and improvement of dementia and neurodegenerative diseases, and actively promote collaborative projects with major domestic pharmaceutical companies and academic institutions.
